Fig. 6: Decreased PTBP3 expression blocks the PI3K/AKT signaling pathway and depresses proliferation, migration, and invasion in HCC cells.
From: MiR-297 inhibits tumour progression of liver cancer by targeting PTBP3
HCC cell lines were treated with miR-297 mimic, miR-297 inhibitor, NC, LY294002, miR-297 inhibitor + si-PTBP3, or miR-297 inhibitor + LY294002. CCK-8 assays (A), cell cycle distribution (B), wound healing (C) and transwell assays (D) of HepG2 cells transfected with si-PTBP3 or si-NC were performed. E–H Overexpression of PTBP3 reversed the suppression of miR-297 overexpression on the proliferation (E), migration (F) and invasion (G) and the cell cycle arrest effect (H) of HepG2 cells. I Western blot analysis of protein expression of PTBP3 and PI3K/AKT signaling pathway-related factors in HCC cell lines. CCK-8 assays (J), wound healing (K) and transwell assays (L) of HepG2 cells transfected with treated with miR-297 mimic, miR-297 inhibitor, NC, LY294002, miR-297 inhibitor + si-PTBP3, or miR-297 inhibitor + LY294002 were performed. *p < 0.05 vs. HCC cells treated with NC. #p < 0.05 vs. HCC cells treated with miR-297 inhibitor. The cell experiments were repeated 3 times. *P < 0.05, **P < 0.01 and ***P < 0.001.
